{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T13:05:55Z","timestamp":1791378355105,"version":"4.3.2"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T00:00:00Z","timestamp":1788825600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T00:00:00Z","timestamp":1788825600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin J Gastroenterol"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1007\/s12328-026-02447-5","type":"journal-article","created":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T06:02:05Z","timestamp":1788847325000},"page":"1009-1017","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["First-line systemic therapy for advanced or metastatic esophageal squamous cell carcinoma: clinical implications for treatment selection after KEYNOTE-590, CheckMate 648, and RATIONALE-306"],"prefix":"10.1007","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1994-4795","authenticated-orcid":false,"given":"Tamotsu","family":"Sagawa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroyuki","family":"Nagashima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koshi","family":"Fujikawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,8]]},"reference":[{"issue":"10302","key":"2447_CR1","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1016\/S0140-6736(21)01234-4","volume":"398","author":"J-M Sun","year":"2021","unstructured":"Sun J-M, Shen L, Shah MA, et al. Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a randomised, placebo-controlled, phase 3 study. Lancet. 2021;398(10302):759\u201371. https:\/\/doi.org\/10.1016\/S0140-6736(21)01234-4.","journal-title":"Lancet"},{"issue":"5","key":"2447_CR2","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1056\/NEJMoa2111380","volume":"386","author":"Y Doki","year":"2022","unstructured":"Doki Y, Ajani JA, Kato K, et al. Nivolumab combination therapy in advanced esophageal squamous-cell carcinoma. N Engl J Med. 2022;386(5):449\u201362. https:\/\/doi.org\/10.1056\/NEJMoa2111380.","journal-title":"N Engl J Med"},{"issue":"5","key":"2447_CR3","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1016\/S1470-2045(23)00108-0","volume":"24","author":"J Xu","year":"2023","unstructured":"Xu J, Kato K, Raymond E, et al. Tislelizumab plus chemotherapy versus placebo plus chemotherapy as first-line treatment for advanced or metastatic oesophageal squamous cell carcinoma (RATIONALE-306): a global, randomised, placebo-controlled, phase 3 study. Lancet Oncol. 2023;24(5):483\u201395. https:\/\/doi.org\/10.1016\/S1470-2045(23)00108-0.","journal-title":"Lancet Oncol"},{"issue":"7","key":"2447_CR4","doi-asserted-by":"publisher","first-page":"1470","DOI":"10.1200\/JCO.22.02331","volume":"41","author":"MA Shah","year":"2023","unstructured":"Shah MA, Kennedy EB, Alarcon-Rozas AE, et al. Immunotherapy and targeted therapy for advanced gastroesophageal cancer: ASCO guideline. J Clin Oncol. 2023;41(7):1470\u201391. https:\/\/doi.org\/10.1200\/JCO.22.02331.","journal-title":"J Clin Oncol"},{"issue":"10","key":"2447_CR5","doi-asserted-by":"publisher","first-page":"992","DOI":"10.1016\/j.annonc.2022.07.003","volume":"33","author":"R Obermannov\u00e1","year":"2022","unstructured":"Obermannov\u00e1 R, Alsina M, Cervantes A, et al. Oesophageal cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up. Ann Oncol. 2022;33(10):992\u20131004. https:\/\/doi.org\/10.1016\/j.annonc.2022.07.003.","journal-title":"Ann Oncol"},{"key":"2447_CR6","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2025.104134","volume":"10","author":"RL Obermannov\u00e1","year":"2025","unstructured":"Obermannov\u00e1 RL, Leong T, ESMO Guidelines Committee. ESMO clinical practice guideline interim update on the treatment of locally advanced oesophageal and oesophagogastric junction adenocarcinoma and metastatic squamous-cell carcinoma. ESMO Open. 2025;10:104134. https:\/\/doi.org\/10.1016\/j.esmoop.2025.104134.","journal-title":"ESMO Open"},{"issue":"12","key":"2447_CR7","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2025.105854","volume":"10","author":"J-P Metges","year":"2025","unstructured":"Metges J-P, Kato K, Sun J-M, et al. Pembrolizumab plus chemotherapy versus chemotherapy for advanced esophageal cancer: 5-year extended follow-up for the randomized phase III KEYNOTE-590 study. ESMO Open. 2025;10(12):105854. https:\/\/doi.org\/10.1016\/j.esmoop.2025.105854.","journal-title":"ESMO Open"},{"issue":"9","key":"2447_CR8","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.7235","volume":"13","author":"K Kato","year":"2024","unstructured":"Kato K, Doki Y, Chau I, et al. Nivolumab plus chemotherapy or ipilimumab versus chemotherapy in patients with advanced esophageal squamous cell carcinoma (CheckMate 648): 29-month follow-up from a randomized, open-label, phase III trial. Cancer Med. 2024;13(9):e7235. https:\/\/doi.org\/10.1002\/cam4.7235.","journal-title":"Cancer Med"},{"issue":"Suppl 2","key":"2447_CR9","doi-asserted-by":"publisher","first-page":"S1107","DOI":"10.1016\/j.annonc.2025.08.2726","volume":"36","author":"I Chau","year":"2025","unstructured":"Chau I, Ajani JA, Doki Y, et al. Nivolumab plus chemotherapy or ipilimumab vs chemo as first-line treatment for advanced ESCC: 5-year follow-up from CheckMate 648. Ann Oncol. 2025;36(Suppl 2):S1107\u20138. https:\/\/doi.org\/10.1016\/j.annonc.2025.08.2726.","journal-title":"Ann Oncol"},{"issue":"2","key":"2447_CR10","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1007\/s10388-022-00970-1","volume":"20","author":"K Kato","year":"2023","unstructured":"Kato K, Doki Y, Ogata T, et al. First-line nivolumab plus ipilimumab or chemotherapy versus chemotherapy alone in advanced esophageal squamous cell carcinoma: a Japanese subgroup analysis of CheckMate 648. Esophagus. 2023;20(2):291\u2013301. https:\/\/doi.org\/10.1007\/s10388-022-00970-1.","journal-title":"Esophagus"},{"key":"2447_CR11","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1007\/s10388-026-01199-y","volume":"23","author":"T Ogata","year":"2026","unstructured":"Ogata T, Kojima T, Ishihara R, et al. First-line tislelizumab plus chemotherapy versus placebo plus chemotherapy in adults with advanced or metastatic esophageal squamous cell carcinoma: a Japanese subgroup analysis of RATIONALE-306 with \u22653 years of follow-up. Esophagus. 2026;23:501\u201311. https:\/\/doi.org\/10.1007\/s10388-026-01199-y.","journal-title":"Esophagus"},{"issue":"4","key":"2447_CR12","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1007\/s10388-022-00920-x","volume":"19","author":"T Kojima","year":"2022","unstructured":"Kojima T, Hara H, Tsuji A, et al. First-line pembrolizumab plus chemotherapy in Japanese patients with advanced\/metastatic esophageal cancer from KEYNOTE-590. Esophagus. 2022;19(4):683\u201392. https:\/\/doi.org\/10.1007\/s10388-022-00920-x.","journal-title":"Esophagus"},{"issue":"3","key":"2447_CR13","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1007\/s10388-024-01053-z","volume":"21","author":"K Kato","year":"2024","unstructured":"Kato K, Hara H, Tsuji A, et al. First-line pembrolizumab plus chemotherapy for advanced\/metastatic esophageal cancer: 1-year extended follow-up in the Japanese subgroup of the phase 3 KEYNOTE-590 study. Esophagus. 2024;21(3):306\u201318. https:\/\/doi.org\/10.1007\/s10388-024-01053-z.","journal-title":"Esophagus"},{"key":"2447_CR14","doi-asserted-by":"publisher","DOI":"10.1186\/s13000-023-01318-8","volume":"18","author":"C Liu","year":"2023","unstructured":"Liu C, Fang F, Kong Y, et al. Tumor area positivity (TAP) score of programmed death-ligand 1 (PD-L1): a novel visual estimation method for combined tumor cell and immune cell scoring. Diagn Pathol. 2023;18:48. https:\/\/doi.org\/10.1186\/s13000-023-01318-8.","journal-title":"Diagn Pathol"},{"issue":"9","key":"2447_CR15","doi-asserted-by":"publisher","DOI":"10.1016\/j.modpat.2025.100793","volume":"38","author":"M Moehler","year":"2025","unstructured":"Moehler M, Yoon HH, Wagner D-C, et al. Concordance between the PD-L1 tumor area positivity score and combined positive score for gastric or esophageal cancers treated with tislelizumab. Mod Pathol. 2025;38(9):100793. https:\/\/doi.org\/10.1016\/j.modpat.2025.100793.","journal-title":"Mod Pathol"},{"key":"2447_CR16","unstructured":"National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology (NCCN Guidelines\u00ae): esophageal and esophagogastric junction cancers. Version 3.2026. June 3, 2026. https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/esophageal.pdf. Accessed 14 July 2026"},{"issue":"1","key":"2447_CR17","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-025-92657-7","volume":"15","author":"K Shiraishi","year":"2025","unstructured":"Shiraishi K, Okada M, Yamamoto S, et al. The efficacy and safety of FOLFOX therapy for advanced esophageal squamous cell carcinoma. Sci Rep. 2025;15(1):8031. https:\/\/doi.org\/10.1038\/s41598-025-92657-7.","journal-title":"Sci Rep"},{"key":"2447_CR18","doi-asserted-by":"publisher","DOI":"10.1007\/s10388-026-01227-x","author":"N Ogura","year":"2026","unstructured":"Ogura N, Yamamoto S, Morita R, et al. FOLFOX plus nivolumab combination therapy for cisplatin-unfit patients with untreated advanced esophageal squamous cell carcinoma. Esophagus. 2026. https:\/\/doi.org\/10.1007\/s10388-026-01227-x.","journal-title":"Esophagus"},{"issue":"Suppl 2","key":"2447_CR19","doi-asserted-by":"publisher","first-page":"S1621","DOI":"10.1016\/j.annonc.2025.09.094","volume":"36","author":"J-M Sun","year":"2025","unstructured":"Sun J-M, Kim S-B, Ogata T, et al. LBA79 Lenvatinib plus pembrolizumab and chemotherapy versus pembrolizumab and chemotherapy in untreated metastatic esophageal squamous cell carcinoma: the randomized phase III LEAP-014 study. Ann Oncol. 2025;36(Suppl 2):S1621\u20132. https:\/\/doi.org\/10.1016\/j.annonc.2025.09.094.","journal-title":"Ann Oncol"},{"issue":"6","key":"2447_CR20","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1159\/000535186","volume":"102","author":"T Sugase","year":"2024","unstructured":"Sugase T, Kanemura T, Takeoka T, et al. Clinical impact of early tumour shrinkage in metastatic or unresectable oesophageal cancer treated with pembrolizumab plus chemotherapy. Oncology. 2024;102(6):484\u201393. https:\/\/doi.org\/10.1159\/000535186.","journal-title":"Oncology"}],"container-title":["Clinical Journal of Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12328-026-02447-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12328-026-02447-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12328-026-02447-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T12:43:05Z","timestamp":1791376985000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12328-026-02447-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,8]]},"references-count":20,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["2447"],"URL":"https:\/\/doi.org\/10.1007\/s12328-026-02447-5","relation":{},"ISSN":["1865-7257","1865-7265"],"issn-type":[{"value":"1865-7257","type":"print"},{"value":"1865-7265","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,8]]},"assertion":[{"value":"27 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 September 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Conflicts of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Ethics approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":3,"name":"Ethics","label":"Informed consent","group":{"name":"EthicsHeading","label":"Declarations"}}]}}